How do you approach patients with AL amyloidosis with t(11;14) who have not achieved a hematologic complete response to induction therapy with 6 cycles of Dara-CyBorD?

Specifically, in the setting of patients that have had a PR or VGPR and are not actively progressing.

Answer from: Medical Oncologist at Academic Institution

Excellent question, and always a frustrating scenario because of how excitedly we discuss the rise of daratumumab with our newly diagnosed patients when they're diagnosed and feeling terrible.I assume the patient here doesn't have any myeloma-defining events, which is a story for another day (and pr...

Comments

Medical Oncologist at University of Chicago
Great answer - would you continue Dara if still in...

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Excellent point, and I realized I didn't comment o...

Medical Oncologist at Los Angeles VA Medical Center
Hi Dr. @Rahul Banerjee -- can you expand on why yo...

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Great question @Anthony Bejjani - largely voodoo f...

Medical Oncologist at University of Chicago
The whole idea about lenalidomide not being used i...

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Very glad I asked you @Ben Derman - I thought this...

Please select the option that best describes you:

How do you approach patients with AL amyloidosis with t(11;14) who have not achieved a hematologic complete response to induction therapy with 6 cycles of Dara-CyBorD?

Related Questions